BioSpace News Archive

Viatris Inc., a global pharmaceutical company, announced that it has been named to Forbes’ list of World’s Best Employers 2022.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has scheduled the release of its 2022 third quarter results for Tuesday, November 1, 2022 before the market opens.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoing global Phase 1 KN-8701 trial evaluating KIN-2787, an investigational pan-RAF inhibitor, in patients with BRAF-altered solid tumors and/or who have NRAS mutant melanoma.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H. C. Wainwright 6th Annual NASH Investor Conference.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted fourteen new employees options to purchase a total of 35,200 shares of the Company’s common stock at an exercise price per share of $26.15, which was the closing price on October 10, 2022, and restricted stock units to acquire a total of 17,600 shares of the Company’s common stock.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the presentation of preclinical data from its Duchenne muscular dystrophy (DMD) programs for the treatment of individuals with DMD mutations amenable to skipping exons 51 or 53.